-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
HC Wainwright Trims Imago BioSciences (NASDAQ:IMGO) Target Price to $35.00
HC Wainwright Trims Imago BioSciences (NASDAQ:IMGO) Target Price to $35.00
Imago BioSciences (NASDAQ:IMGO – Get Rating) had its price objective cut by HC Wainwright from $36.00 to $35.00 in a research report released on Tuesday, MarketBeat reports. They currently have a buy rating on the stock.
Imago BioSciences Stock Down 0.8 %
Shares of Imago BioSciences stock opened at $19.09 on Tuesday. Imago BioSciences has a 12-month low of $11.56 and a 12-month high of $35.68. The stock has a market cap of $644.10 million and a P/E ratio of -10.72. The business's 50 day moving average is $15.43 and its 200-day moving average is $17.73.
Get Imago BioSciences alerts:Insider Activity at Imago BioSciences
In related news, insider Jennifer Peppe sold 5,598 shares of the stock in a transaction on Monday, August 15th. The stock was sold at an average price of $19.41, for a total value of $108,657.18. Following the sale, the insider now owns 148,809 shares in the company, valued at approximately $2,888,382.69. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last quarter, insiders have sold 7,721 shares of company stock worth $147,356. Company insiders own 14.90% of the company's stock.
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the stock. FMR LLC grew its position in Imago BioSciences by 4.4% in the second quarter. FMR LLC now owns 5,060,365 shares of the company's stock valued at $67,759,000 after acquiring an additional 212,359 shares during the last quarter. BlackRock Inc. lifted its stake in Imago BioSciences by 146.2% in the first quarter. BlackRock Inc. now owns 3,290,894 shares of the company's stock valued at $63,415,000 after buying an additional 1,954,112 shares during the period. Frazier Life Sciences Management L.P. acquired a new position in Imago BioSciences in the first quarter valued at approximately $57,256,000. Citadel Advisors LLC increased its holdings in shares of Imago BioSciences by 0.7% during the second quarter. Citadel Advisors LLC now owns 2,517,041 shares of the company's stock valued at $33,703,000 after acquiring an additional 18,620 shares in the last quarter. Finally, Woodline Partners LP increased its holdings in shares of Imago BioSciences by 101.9% during the fourth quarter. Woodline Partners LP now owns 848,129 shares of the company's stock valued at $20,109,000 after acquiring an additional 428,127 shares in the last quarter. Institutional investors own 88.28% of the company's stock.About Imago BioSciences
(Get Rating)
Imago BioSciences, Inc, a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera.
See Also
- Get a free copy of the StockNews.com research report on Imago BioSciences (IMGO)
- Is Sanofi A Buy, Despite Recent Stumbles?
- If You Hate Speed Cameras, Then You'll Like Verra Mobility Stock
- Institutional Support For TJX Companies May Cap Gains
- Starbucks Stock, Is Brand Loyalty Enough Reason to Buy
- BJ's Wholesale Club Pops, Will Costco Be Next?
Receive News & Ratings for Imago BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imago BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.
Imago BioSciences (NASDAQ:IMGO – Get Rating) had its price objective cut by HC Wainwright from $36.00 to $35.00 in a research report released on Tuesday, MarketBeat reports. They currently have a buy rating on the stock.
據MarketBeat報道，在週二發佈的一份研究報告中，雲萊特將Imago BioSciences(納斯達克代碼：IMGO-GET)的目標價從36.00美元下調至35.00美元。他們目前對該股的評級為買入。
Imago BioSciences Stock Down 0.8 %
Imago BioSciences股價下跌0.8%
Shares of Imago BioSciences stock opened at $19.09 on Tuesday. Imago BioSciences has a 12-month low of $11.56 and a 12-month high of $35.68. The stock has a market cap of $644.10 million and a P/E ratio of -10.72. The business's 50 day moving average is $15.43 and its 200-day moving average is $17.73.
Imago BioSciences的股票週二開盤報19.09美元。Imago BioSciences的股價為11.56美元，為12個月低點，12個月高位為35.68美元。該股市值為6.441億美元，市盈率為-10.72倍。該業務的50日移動均線切入位在15.43美元，200日移動均線切入位在17.73美元。
Insider Activity at Imago BioSciences
Imago BioSciences的內部活動
In related news, insider Jennifer Peppe sold 5,598 shares of the stock in a transaction on Monday, August 15th. The stock was sold at an average price of $19.41, for a total value of $108,657.18. Following the sale, the insider now owns 148,809 shares in the company, valued at approximately $2,888,382.69. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last quarter, insiders have sold 7,721 shares of company stock worth $147,356. Company insiders own 14.90% of the company's stock.
在相關新聞中，內部人士珍妮弗·佩佩在8月15日星期一的一次交易中出售了5598股該股。這隻股票的平均售價為19.41美元，總價值為108,657.18美元。出售後，這位內部人士現在擁有該公司148,809股，價值約2,888,382.69美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的，可以通過這個超鏈接訪問該文件。在上個季度，內部人士出售了7721股公司股票，價值147,356美元。公司內部人士持有該公司14.90%的股份。
Institutional Inflows and Outflows
機構資金流入和流出
About Imago BioSciences
關於Imago BioSciences
(Get Rating)
(獲取評級)
Imago BioSciences, Inc, a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera.
臨牀階段生物製藥公司Imago BioSciences，Inc.發現和開發了針對賴氨酸特異性脱甲基酶1(LSD1)的小分子產品候選產品，LSD1是一種用於生產骨髓中血細胞的酶。它的主要候選產品是Bomedemstat，正在進行第二階段臨牀試驗，用於治療骨髓增生性腫瘤和慢性骨髓癌，如骨髓纖維化、原發性血小板增多症和真性紅細胞增多症。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on Imago BioSciences (IMGO)
- Is Sanofi A Buy, Despite Recent Stumbles?
- If You Hate Speed Cameras, Then You'll Like Verra Mobility Stock
- Institutional Support For TJX Companies May Cap Gains
- Starbucks Stock, Is Brand Loyalty Enough Reason to Buy
- BJ's Wholesale Club Pops, Will Costco Be Next?
- 免費獲取StockNews.com關於Imago BioSciences(IMGO)的研究報告
- 儘管賽諾菲最近跌跌撞撞，但它是買入的嗎？
- 如果你討厭超速攝像頭，那麼你會喜歡Verra Mobility Stock
- 對TJX公司的機構支持可能限制漲幅
- 星巴克股票，品牌忠誠度足以成為購買理由嗎
- BJ‘s批發俱樂部流行音樂，Costco會是下一個嗎？
Receive News & Ratings for Imago BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imago BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受Imago生物科學日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Imago BioSciences和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧